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 Microvascular obstruction (MVO), which represents failed myocardial reperfusion, 78 
occurs in about half of patients treated with standard primary percutaneous coronary 79 
intervention (PCI), and predicts a worse prognosis.1 Distal embolization and microvascular 80 
thrombosis contribute to MVO. In the T-TIME trial (NCT02257294),2 we hypothesized that 81 
low-dose intracoronary fibrinolysis with alteplase, in patients with adequate anticoagulation 82 
undergoing primary PCI, would reduce MVO extent as assessed by contrast enhanced 83 
cardiovascular magnetic resonance imaging. We found that MVO did not differ with 84 
alteplase vs. placebo.2 Here, we report the efficacy and safety of intracoronary alteplase at 1-85 
year.  86 
From August 2016 to December 2017, patients with acute ST-segment elevation 87 
myocardial infarction from 11 U.K. hospitals were prospectively enrolled. The trial design 88 
and main results have been described previously.2 T-TIME was an investigator-initiated, 89 
double-blind, parallel-group, randomized, placebo-controlled clinical trial. Patients were 90 
eligible if they presented with persistent ST-elevation or recent left bundle branch block, ≤6 91 
hours from symptom onset, and either an occluded culprit artery, or impaired flow (TIMI 92 
[Thrombolysis in Myocardial Infarction] flow grade 2) with TIMI thrombus grade ≥2. The 93 
study was approved by the West of Scotland Research Ethics Committee (reference 13-WS-94 
0119). Informed consent was obtained. 95 
Patients were randomized to placebo, alteplase 10mg, or alteplase 20mg, on a 1:1:1 96 
basis. The intervention was administered before stent implantation by manual infusion of the 97 
20ml volume of study into the culprit artery proximal to the lesion. Serious adverse events 98 
with potential relevance to the pre-defined clinical outcomes, were adjudicated by a blinded 99 
clinical event committee. Analysis of efficacy outcomes was according to treatment as 100 
randomized. Analysis of major bleeds was based on treatment received. Logistic regression 101 
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(adjusted for infarct location) was used to assess for treatment effects. Statistical analyses 102 
were performed with Rv3.2.4, according to a pre-specified statistical analysis plan. 103 
Four hundred and forty patients (mean age 61±10 years, 85% male) were randomized 104 
to placebo (n=151), alteplase 10mg (n=144) and alteplase 20mg (n=145) (Figure). At 1-year, 105 
there was no difference in MACE (major adverse cardiac events) with alteplase 20mg (n=15 106 
[10.3%]) vs. placebo (n=16 [10.6%]) (OR [odds ratio]: 0.96 [95% CI (confidence interval): 107 
0.45, 2.04]), or with alteplase 10mg (n=22 [15.3%]) vs. placebo (OR: 1.52 [95% CI: 0.76, 108 
3.05]). There was no difference in spontaneous MACE (MACE excluding MI associated with 109 
revascularization) at 1-year with alteplase 20mg (n=14 [ 9.7%]) vs. placebo (n=16 [10.6%]) 110 
(OR: 0.89 [95% CI: 0.42, 1.91]), or with alteplase 10mg (n=18 [12.5%]) vs. placebo (OR: 111 
1.19 [95% CI: 0.58, 2.46]). MI associated with revascularization occurred in 2, 4 and 1 112 
patients at 1-year, randomized to placebo, alteplase 10mg and alteplase 20mg respectively 113 
(log rank p=0.351). 114 
MACCE (major adverse cardiovascular and cardiac events), defined as cardiovascular 115 
death, non-fatal MI, or unplanned hospitalization for stroke, or transient ischemic attack, did 116 
not differ between treatment groups at 1-year (alteplase 20mg [n=10 (6.9%)] vs. placebo 117 
[n=7 (4.6%)]: OR: 1.54 [95% CI: 0.57, 4.16]; or alteplase 10mg [n=9 (6.3%)] vs. placebo: 118 
OR: 1.38 [95% CI: 0.50, 3.83]). Similarly, there was no difference in the composite of all-119 
cause mortality and heart failure hospitalization, with alteplase 20mg (n=13 [9.0%]) vs. 120 
placebo (n=14 [9.3%]) (OR: 0.95 [95% CI: 0.43, 2.12]), or with alteplase 10mg (n=19 121 
[13.2%]) vs. placebo (OR: 1.48 [95% CI: 0.71, 3.12]). There was no difference in heart 122 
failure hospitalizations at 1-year with alteplase 20mg (n=10 [6.9%]) vs. placebo (n=13 123 
[8.6%]) (OR: 0.76 [95% CI: 0.32, 1.84]), or with alteplase 10mg (n=15 [10.4%]) vs. placebo 124 
(OR: 1.22 [95% CI: 0.55, 2.72]). There was no difference in all-cause death at 1-year, with 125 
placebo (n=1 [0.7%]), alteplase 10mg (n=6 [4.2%]), or alteplase 20mg (n=3 [2.1%]) (log-126 
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rank p=0.127). BARC (Bleeding Academic Research Consortium) type 3-5 bleeds occurred 127 
in 1, 2 and 2 patients, with placebo, alteplase 10mg and alteplase 20mg (log-rank p=0.792). 128 
In summary, clinical outcomes at 1-year were not improved by adjunctive, low-dose, 129 
intracoronary fibrinolysis. Bleeds were uncommon (1.1%) and consistent with what would be 130 
expected in a contemporary primary-PCI population. These results should be interpreted as 131 
exploratory because the T-TIME trial was designed but not powered to examine 1-year 132 
clinical outcomes.  133 
Potential for harm with facilitated PCI, using full- or half-dose fibrinolytic therapy 134 
given intravenously pre-PCI, was shown in the ASSENT-43 and FINESSE4 trials. 135 
Intravenous fibrinolytic therapy pre-PCI improved initial culprit artery patency, but increased 136 
residual thrombus, ischemic complications and major bleeds, compared to standard primary 137 
PCI.5 These results could be explained by inadequate anticoagulation compounded by any 138 
paradoxical prothrombotic effects of lytic therapy in P2Y12 inhibitor naive-patients.  139 
 Current trials of adjunctive intracoronary fibrinolysis during primary PCI include 140 
RESTORE-MI [NCT03998319], STRIVE [NCT0335839], and OPTIMAL [NCT02894138]. 141 
Further research should build on the new knowledge arising from T-TIME, to elucidate 142 
which patient groups might benefit.   143 
In conclusion, low-dose intracoronary alteplase administered early during primary 144 
PCI did not improve clinical outcomes. Further research is warranted to identify new 145 
treatments for MVO.  146 
 147 
 148 
 149 
 150 
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Figure. Screening, randomization, treatment, and follow up at one year. 176 
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MRI = magnetic resonance imaging; STEMI = ST-segment elevation myocardial infarction 179 
 180 
 181 
 182 
 183 
 184 
 185 
 186 
 187 
                                                                            CONFIDENTIAL – UNDER EMBARGO  
1 
 
9 
Funding Sources  188 
This work was supported by an NIHR EME Grant (12/170/45) and Boehringer Ingelheim 189 
provided the study drugs. AMM was funded by a Fellowship from the British Heart 190 
Foundation (BHF, reference FS/16/74/32573). CB and MCP are supported by BHF 191 
RE/18/6/34217. The research was part-supported by the National Institute for Health 192 
Research (NIHR) infrastructure at Leeds. The views expressed are those of the author(s) and 193 
not necessarily those of the NHS, the NIHR or the department of health. 194 
Role of Funder Statement 195 
The funder, NIHR-EME, coordinated peer review, approved the design of the study and had 196 
oversight of its conduct and management 197 
Role of Sponsor Statement 198 
The University of Glasgow and Greater Glasgow and Clyde Health Board were independent 199 
co-sponsors of the trial. The co-sponsors shared oversight and responsibility for the design 200 
and conduct of the study; collection, management, research governance, analysis, and final 201 
approval of the manuscript. The sponsor did not have the right to preclude submission of the 202 
manuscript.  203 
                                                                            CONFIDENTIAL – UNDER EMBARGO  
1 
 
10 
Conflict of Interest Disclosures 204 
Annette M. Maznyczka – Fellowship from the British Heart Foundation (reference 205 
FS/16/74/32573) 206 
Peter J. McCartney – none 207 
Hany Eteiba – none 208 
Robin A. Weir – none 209 
Aengus Murphy – none 210 
Colin J. Petrie - none 211 
John P. Greenwood – none 212 
Douglas F. Muir – none 213 
Saqib Chowdhary – none 214 
Anthony H. Gershlick – none 215 
Clare Appleby – none 216 
James M. Cotton – none 217 
Andrew Wragg – none 218 
Nick Curzen – has received an unrestricted research grant and fees for lectures and 219 
consultancy from Abbott Vascular and Boston Scientific. 220 
Keith G. Oldroyd – none 221 
Mitchell Lindsay – none 222 
Margaret McEntegart – none  223 
Paul Rocchiccioli – none 224 
Aadil Shaukat – none 225 
Richard Good – none 226 
Stuart Watkins – none 227 
Keith Robertson – none 228 
Christopher Malkin – none 229 
Lynn Martin – none  230 
Lynsey Gillespie – none 231 
Nitesh Ramparsad – none 232 
Kirsty Wetherall - none 233 
Thomas J. Ford – none 234 
Mark C. Petrie – none 235 
Keith A. Fox – has received grants and personal fees from Bayer/Janssen, grants from 236 
AstraZeneca, personal fees from Sanofi/Regeneron and Verseon. 237 
Ian Ford – none 238 
Alex McConnachie – has received grants from Medical Research Council / NIHR-EME 239 
program during the conduct of the study 240 
Colin Berry – based on contracts with the University of Glasgow, Professor Berry has held 241 
research and/or consultancy agreements with Abbott Vascular, AstraZeneca, Boehringer 242 
Ingelheim, HeartFlow, GSK, Novartis, Philips and Siemens Healthcare. He has held grants 243 
from NIHR-EME (reference 12/170/45) and the British Heart Foundation (reference 244 
FS/16/74/32573; RE/18/6/34217) in support of the current study. 245 
None of the other investigators or committee members have any relevant potential conflict of 246 
interest to declare. 247 
                                                                            CONFIDENTIAL – UNDER EMBARGO  
1 
 
11 
Acknowledgements 248 
Responsible individual at Data Coordinating Centre: Alex McConnachie 249 
Data Coordinating Centre(s): Robertson Centre for Biostatistics, Glasgow Clinical Trials 250 
Unit, University of Glasgow 251 
Author contributions: 252 
Hany Eteiba, John P. Greenwood, Douglas F. Muir, Saqib Chowdhary, Anthony H Gershlick, 253 
Clare Appleby, James M. Cotton, Andrew Wragg, and Nick Curzen, were Local Principal 254 
Investigators, obtained informed consent and randomized patients, collected data, interpreted 255 
the results and contributed to the manuscript. 256 
 257 
Annette M. Maznyczka and Peter J. McCartney contributed to screening and enrolment, 258 
collected the data, undertook data analyses and interpreted the data.  259 
 260 
Annette M. Maznyczka wrote the original draft of the manuscript. 261 
 262 
Annette M. Maznyczka, Thomas J. Ford and Colin Berry served as blinded primary 263 
reviewers of serious adverse events, of potential relevance 264 
 265 
Mark C. Petrie helped to design the charter for the clinical event committee, interpreted the 266 
data and contributed to the manuscript. 267 
 268 
Robin A. Weir chaired the clinical event committee. 269 
 270 
Robin A. Weir, Aengus Murphy and Colin J. Petrie adjudicated clinical events, as part of the 271 
clinical event committee.  272 
 273 
Keith G. Oldroyd, Mitchell Lindsay, Margaret McEntegart, Paul Rocchiccioli, Aadil Shaukat, 274 
Richard Good,
 Stuart Watkins, Keith Robertson, and Christopher Malkin, obtained informed 275 
consent and randomized patients, collected data, interpreted the results and contributed to the 276 
manuscript. 277 
                                                                            CONFIDENTIAL – UNDER EMBARGO  
1 
 
12 
 278 
Lynn Martin supported screening and enrolment, data collection, and event reporting.  279 
 280 
Lynsey Gillespie was Project Manager for the trial.  281 
 282 
Keith A. Fox chaired the Trial Steering Committee and contributed to the interpretation of the 283 
data and the manuscript. 284 
 285 
Ian Ford contributed to the study design, data analyses and interpretation, and contributed to 286 
the manuscript. 287 
 288 
Alex McConnachie, Nitish Ramparsad and Kirsty Wetherall analyzed and interpreted the 289 
data and contributed to the manuscript. 290 
 291 
Colin Berry conceived the study, obtained the funding, recruited and randomized patients, 292 
collected and assessed data blind to treatment group assignment, and interpreted the results. 293 
 294 
Colin Berry is Chief Investigator and Saqib Chowdhary, Ian Ford, John P. Greenwood, 295 
Douglas Muir, and Keith G. Oldroyd were co-applicants on the grant from the National 296 
Institute for Health Research – Efficacy and Mechanism Evaluation (NIHR EME) 297 
programme (reference: 12/170/45). 298 
 299 
We acknowledge the clinical staff and the patients who participated in this project. 300 
 301 
 302 
 303 
 304 
 305 
